keoung ik Na
Chuncheon, anyang, 135-060, South Korea
Completed
NCT Number: NCT01053858
Triamcinolone or Bevacizumab for Central Retinal Vein Occlusion With Poor Vision
To evaluate the effect of intravitreal bevacizumab with intravitreal triamcinolone for the treatment of central retinal vein occlusion (CRVO) presenting poor visual acuity.
Completed
Looking for future studies?
Notify MeKey information
Age range
20 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- central macular thickness of more than 250 μm and baseline visual acuity of 20/200 or worse than 20/200 in patient with central retinal vein occlusion
Exclusion criteria
- previous treatment such as intravitreal injection, subtenon injection, or laser photocoagulation since the time of onset
- Patients with a history of glaucoma, neovascular glaucoma, diabetic retinopathy, and macular disorders
- neovascularization on the disc or elsewhere or rubeosis
Treatment and study plan
intravitreal injection
Procedureintravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
Primary outcomes
-
best corrected visual acuity
Time frame: baseline, 1 month, 2 months, 3 months, 6 months, 12 months
Secondary outcomes
-
central macular thickness by optical coherence tomography
Time frame: baseline, 1 month, 2 months, 3 months, 6 months 12months
Sponsors and collaborators
Lead sponsor
Hallym University Medical Center
Other
Registry information
Important dates
- Study start
- 2008
- Primary completion
- 2009
- Study completion
- 2010
- First posted
- Jan 22, 2010
- Registry last updated
- Jan 22, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.